| Literature DB >> 33198760 |
Lauren H Wyatt1, Robert B Devlin2, Ana G Rappold2, Martin W Case2, David Diaz-Sanchez2.
Abstract
BACKGROUND: Fine particulate matter (PM2.5) related mild inflammation, altered autonomic control of cardiovascular function, and changes to cell function have been observed in controlled human exposure studies.Entities:
Keywords: Controlled exposure; Healthy human volunteers; Particulate matter air pollution; Systemic inflammatory effect
Mesh:
Substances:
Year: 2020 PMID: 33198760 PMCID: PMC7670817 DOI: 10.1186/s12989-020-00389-5
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
Descriptive statistics of the study population (n = 20)
| Demographic variable Mean (+/- SD) | Mean (+/- SD) |
|---|---|
| Sex (%) | |
| Male | 65% |
| Female | 35% |
| Race (%) | |
| White | 70% |
| Black | 20% |
| Mixed (W/B) | 10% |
| Age (years) | 25.3 ± 4.0 |
| BMI (kg/m2) | 25.5 ± 3.6 |
Average PM2.5 concentration (± standard deviation) for clean air and concentrated PM2.5 exposures (μg/m3)
| Exposure Treatment | Mean (± SD) |
|---|---|
| Clean air | 2.1 ± 2.6 |
| Concentrated PM2.5 | 37.8 ± 6.5 |
Fig. 1Mean percent point change in lung function (95%CI): 1 h after exposure (Post) and approximately 20 h after exposure (Follow-up). Mean change is expressed per 37.8 μg/m3 of PM2.5, which corresponds to average concentrated PM2.5 exposure across subjects
Changes in blood chemistry, cellular, HRV, inflammatory, lung function, and repolarization measures (95%CI): 1 h after exposure (Post) and approximately 20 h after exposure (Follow-up). Mean change is expressed per 37.8 μg/m3 of PM2.5, which corresponds to average concentrated PM2.5 exposure across subjects
| Group | Endpoint | Post | Follow-up |
|---|---|---|---|
| Blood Chemistry | Cholesterol (mg/dL) | 1.4 (− 3.0, 5.9) | 0.6 (− 3.1, 4.4) |
| HDL (mg/dL) | − 0.4 (− 5.3, 4.6) | − 1.4 (− 6.3, 3.6) | |
| LDL (mg/dL) | 5.5 (− 3.7, 14.6) | 4.3 (− 1.9, 10.8) | |
| Triglycerides (mg/dL) | − 14.3 (− 40.5, 13.3) | − 17.3 (− 41.2, 6.6) | |
| VLDL (mg/dL) | − 12.9 (− 38.4, 13.9) | −16.8 (− 41.2, 7.6) | |
| D-Dimer (ng/mL) | 10.7 (− 12.1, 33) | − 4.4 (− 21.5, 12.6) | |
| LDH (IU/L) | − 6.9 (− 13.3, − 0.5) | − 11.2 (− 17.4, − 5.0) | |
| PAI-1 (ng/mL) | −1.2 (− 16.2, 13.6) | 7.0 (− 15.9, 29.3) | |
| Plasminogen (%) | 2.2 (− 5.1, 9.6) | 1.7 (− 6.9, 10.4) | |
| Protein (g/dL) | − 0.2 (− 3.2, 2.8) | 0.1 (− 1.9, 2.2) | |
| tPA (ng/mL) | 3.9 (− 3.8, 11.4) | − 3.5 (− 13.1, 5.8) | |
| vWF (%) | − 6.9 (− 23.0, 9.2) | 6.0 (− 7.5, 19.5) | |
| Cellular | Basophils (%) | − 3.6 (− 51.2, 44.0) | − 0.4 (− 38.1, 40.4) |
| Eosinophils (103 cells/uL) | − 38.4 (− 146.2, 70.8) | − 4.5 (− 19.6, 11.5) | |
| Eosinophils (%) | 1.2 (− 15.8, 18.3) | 2.1 (− 16.9, 21.7) | |
| Lymphocytes (%) | 2.1 (− 3.5, 7.7) | 6.3 (− 0.9, 14.2) | |
| Monocytes (103 cells/uL) | − 2.2 (− 13.8, 9.1) | − 2.6 (− 14.2, 8.3) | |
| Monocytes (%) | 0.8 (− 11.1, 12.3) | 2.9 (− 8.1, 13.6) | |
| Neutrophils (%) | −6.5 (− 13.9, 0.8) | −5.7 (− 11.1, − 0.6) | |
| Platelets (103 cells/uL) | − 0.8 (− 6.3, 4.8) | − 0.5 (− 4.7, 3.8) | |
| RBC (103 cells/uL) | − 0.5 (− 2.5, 1.4) | − 1.6 (− 3.2, 0.0) | |
| WBC (103 cells/uL) | 3.3 (− 11.8, 18.5) | −4.8 (− 14.1, 4.5) | |
| HRV | HF/LF | 12.7 (− 17.4, 42.7) | 17.0 (− 31.3, 65.2) |
| HFn | 8.6 (− 6.4, 23.7) | 13.0 (− 12.8, 38.7) | |
| LFn | −0.7 (− 19.1, 16.6) | − 13.3 (− 31.3, 4.8) | |
| pNN50 (# of NN intervals) | 2.0 (− 33.8, 38.0) | 154.5 (− 178.2, 487.2) | |
| SDNN (ms) | −6.6 (− 25.2, 12.0) | 10.6 (− 21.8, 43.0) | |
| Inflammatory | CRP (ng/mL) | 9.1 (1.0, 17.2) | 22.8 (−2.9, 48.7) |
| IL-1b (pg/mL) | −3.0 (− 14.7, 8.7) | 1.9 (−8.7, 13.1) | |
| IL-6 (pg/mL) | 12.7 (−9, 34.4) | −3.0 (− 17.3, 11.5) | |
| IL-8 (pg/mL) | −1.5 (−9.9, 7.0) | 0.8 (− 13.2, 14.8) | |
| sICAM (ng/mL) | 10.7 (4., 17.5) | 6.5 (−1.7, 14.7) | |
| SAA (ng/mL) | 8.7 (1.3, 16.1) | 34.6 (13.1, 56.1) | |
| sVCAM (ng/mL) | 6.6 (1.3, 12.0) | 2.5 (−3.9, 8.9) | |
| TNF-a (pg/mL) | −1.4 (−6.1, 3.3) | 0.2 (−7.1, 7.5) | |
| Lung function | FEF 25–75% | −1.6 (−4.3, 1.1) | 0.6 (−2.4, 3.5) |
| FEV1 | −0.8 (−1.7, 0.0) | 0.6 (− 0.8, 1.8) | |
| FEV1/FVC | −1.2 (− 2.4, − 0.1) | 0.0 (− 1.2, 1.2) | |
| FVC | 0.2 (− 0.8, 1.1) | 0.9 (− 0.6, 2.4) | |
| PEF | − 1.8 (−3.7, 0.1) | − 1.0 (− 3.6, 1.6) | |
| Repolarization | Max HR (beats per min) | −3.3 (−9.3, 2.6) | 1.9 (−6.5, 10.2) |
| Mean HR (beats per min) | − 1.9 (−8.6, 4.5) | −0.4 (−6.2, 5.5) | |
| Min HR (beats per min) | −0.9 (−9.3, 7.6) | −1.7 (− 9.7, 6.2) | |
| P-wave (ms) | 10.5 (4.0, 17.1) | −5.7 (− 20, 8.7) | |
| QRS complex (ms) | 2.2 (−1.6, 6.0) | −4.6 (−9.9, 0.7) | |
| QT interval (ms) | −0.1 (−1.7, 1.5) | 0.4 (−2.2, 3.1) | |
| QTc interval (ms) | −0.3 (−1.1, 0.6) | 0.1 (−1.6, 1.7) | |
| T-wave (ms) | −0.9 (−9.7, 7.9) | −6.1 (−13.2, 1.2) |
Fig. 2Mean percent point change in systemic inflammation markers (95%CI): 1 h after exposure (Post) and approximately 20 h after exposure (Follow-up). Mean change is expressed per 37.8 μg/m3 of PM2.5, which corresponds to average concentrated PM2.5 exposure across subjects
Fig. 3Mean percent point change in HRV and cardiac repolarization measures (95%CI): 1 h after exposure (Post) and approximately 20 h after exposure (Follow-up). Mean change is expressed per 37.8 μg/m3 of PM2.5, which corresponds to average concentrated PM2.5 exposure across subjects
Fig. 4Mean percent point change in blood chemistry and lipids measures (95%CI): 1 h after exposure (Post) and approximately 20 h after exposure (Follow-up). Mean change is expressed per 37.8 μg/m3 of PM2.5, which corresponds to average concentrated PM2.5 exposure across subjects